Objective:
To compare the durability of OTX-TKI (Axpaxli) versus aflibercept in patients with neovascular AMD, specifically focusing on the time to first rescue injection.
Key Findings:
- Patients treated with aflibercept reached 30% needing the first rescue injection at 28 weeks, while those treated with OTX-TKI reached this mark at 52 weeks, indicating a clinically significant 6-month difference in durability.
Interpretation:
OTX-TKI demonstrates greater durability compared to aflibercept, with a significant delay in the need for rescue injections.
Limitations:
- The study's design may complicate interpretation due to its survival study nature, and data collection ceases once patients are rescued, potentially limiting long-term insights into treatment effects.
Conclusion:
OTX-TKI is well tolerated, safe, and demonstrates unmatched durability of 6 to 12 months in most patients, highlighting its potential as a superior treatment option.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
